Factor 8 Ehl denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for factor 8 ehl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Extended Half-Life Factor VIII as Duplicate Therapy

Humana's duplicate-therapy denial for an extended half-life (EHL) Factor VIII product means the plan has determined that a standard half-life Factor VIII concentrate already on the patient's benefit profile addresses the same indication — hemophilia A — and that the EHL product therefore represents an unnecessary duplication. This denial is common at the transition from standard to EHL Factor VIII and frequently misapplied: EHL products have a pharmacokinetically distinct profile that may allow less frequent infusions or better trough coverage for the same patient.

The clinical distinction between standard and EHL Factor VIII is the heart of the appeal.

## Why It Is Appealable

Duplicate-therapy determinations are medical-necessity decisions. Under ACA §2719, non-grandfathered plans must provide internal appeals and access to independent external review. Under ERISA §503, self-funded plans must give a full-and-fair review with access to the complete claims file. The internal appeal window is 180 days from the denial notice. External review must be filed within four months of the final adverse internal decision. Expedited review — typically 72 hours — is available when clinician-certified health urgency applies; for active hemophilia management, this standard is frequently met.

## Appeal Process and Timeline

1. Request Humana's denial rationale and clinical policy — specifically, the version of Humana's hemophilia coverage policy applied and the reviewer's hematology credentials. 2. Peer-to-peer call — have the treating hematologist call Humana's medical director. The pharmacokinetic distinction between standard and EHL Factor VIII is well established and hematologists are effective advocates at this level. 3. Internal appeal — file within 180 days. Humana's standard pre-service decision timeline is 30 days; urgent/expedited is 72 hours. 4. External review — if the internal appeal fails, file with the IRO within four months. Hematology-specialist IRO reviewers routinely recognize the EHL/standard distinction.

## Documentation to Gather

• Current prophylaxis regimen history — dates of standard Factor VIII use, infusion frequency, actual trough levels from pharmacokinetic studies or clinical estimates, and documented bleeding events on the current regimen.
• Bleeding event log — dates, severity, joint involvement, and treatment required for any breakthrough bleeds on the current standard Factor VIII regimen.
• Hematologist's medical-necessity letter — explaining the pharmacokinetic rationale for transitioning to EHL Factor VIII: specifically how the extended half-life addresses an unmet clinical need (reduced infusion burden enabling adherence, inadequate trough coverage, joint damage trajectory, or pediatric venous access challenges).
• Joint assessment — if joint disease is a factor, imaging or clinical evaluation documenting the extent of hemophilic arthropathy.
• Pharmacokinetic (PK) study results — if available, individual PK testing demonstrating the patient's specific half-life on standard Factor VIII and projected trough improvement with EHL product.
• Applicable guideline reference — note that the prescriber's plan aligns with the relevant hemophilia treatment guideline from the applicable hematology society.

## Criteria-Mapping Structure

Obtain Humana's hemophilia clinical coverage policy and the FDA-approved prescribing label for the specific EHL Factor VIII product. Map each coverage criterion to a chart finding. The key argument in a duplicate-therapy denial is not that the products treat different diseases — they do not — but that they are clinically non-interchangeable for this patient due to pharmacokinetic differences and the individual's specific hemophilia management needs. This distinction, supported by a hematologist's letter and objective bleeding/adherence data, is the standard rebuttal and is routinely accepted at internal appeal or external review.